A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 10, 2009, Pages 1642-1646

  Provencio, Mariano ^a   Sanchez, Antonio ^a   Maximiano, Constanza ^a   Cantos, Blanca ^a   Méndez, Miriam ^a   Bonilla, Félix ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cardiotoxicity; Chemotherapeutic approaches; Lymphoma and Hodgkin disease; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CYCLOPHOSPHAMIDE; CYTOKINES; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SMOKING; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VINCRISTINE;

EID: 70350746397     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903186478     Document Type: Article

References (11)

1. Provencio M, Cerdeira S, Sánchez A, et al. Rapid-infusion rituximab in lymphoma treatment. Ann Oncol 2006;17:1027-1028.
2. Toma MB, Medina PJ. Update on targeted therapy. Focus on monoclonal antibodies. J Pharm Prac 2008;21:4-16.
3. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imagingexecutive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac radionuclide Imaging). Circulation 2003;108:1404-1418.
4. Von Hoff DD, Layard M, Basa P. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979;91:701.
5. Siano M, Lerch E, Negretti L, et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res 2008;14:7935-7939.
6. Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging. J Nucl Cardiol 2006;13:415-426.
7. Singal PK, Lliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905.
8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235-242.
9. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin lymphoma. Ann Oncol 2003;14:277-281.
10. Kilickap S, Yavuz B, Aksoy S, et al. Addition of rituximab to CHOP does not increase the risk of cardiotoxicity in patients with non-Hodgkin lymphoma. Med Oncol 2008;25: 437-442.
11. Elbl L, Vasova I, Tomaskova I, et al. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin lymphoma. Neoplasma 2006;53: 174-181.